---
title: "BIOLIGHT issues a profit warning, expecting a net loss of 45 million to 67.5 million yuan for the year 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225356496.md"
description: "According to the Zhitong Finance APP, BIOLIGHT has released its annual performance forecast for 2024. The company expects a net loss attributable to shareholders of the listed company of RMB 45 million to RMB 67.5 million for the year 2024; the net loss after deducting non-recurring gains and losses is expected to be RMB 67.9 million to RMB 90.4 million"
datetime: "2025-01-17T13:07:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225356496.md)
  - [en](https://longbridge.com/en/news/225356496.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225356496.md)
generator: "portal-rs"
---

# BIOLIGHT issues a profit warning, expecting a net loss of 45 million to 67.5 million yuan for the year 2024

According to the Zhitong Finance APP, BIOLIGHT (300246.SZ) released its annual performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of 45 million to 67.5 million yuan for the year 2024; the net loss after deducting non-recurring gains and losses is expected to be 67.9 million to 90.4 million yuan

### Related Stocks

- [300246.CN](https://longbridge.com/en/quote/300246.CN.md)

## Related News & Research

- [REG - Aberdeen Asian Inc - Director/PDMR Shareholding](https://longbridge.com/en/news/296505605.md)
- [Cell C publishes pro forma financials after Comm Equipment Company merger](https://longbridge.com/en/news/296585930.md)
- [Ximei Resources clarifies tantalum pricing mechanism in Ganfeng Lithium procurement deal](https://longbridge.com/en/news/296362749.md)
- [REG - JTC PLC BNP Paribas SA - Holding(s) in Company](https://longbridge.com/en/news/296253360.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**